Status:
COMPLETED
Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients
Lead Sponsor:
Kidney Cancer Research Bureau
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18-85 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate efficacy and safety of Radiofrequency ablation in metastatic renal cell carcinoma patients with primary tumor less than 5 cm before medical treatment. Ablation...
Detailed Description
Nephrectomy has become an integral part of the management of patients with metastatic kidney cancer. Performing nephrectomy in these patients is not without risk, however. The very real chance of sign...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically proven renal cell carcinoma before RFA;
- Primary tumor no grater than 5 cm;
- CT-confirmed metastatic measurable sites;
- Good prognosis by adapted MSKCC criteria;
- No treatment for RCC;
Exclusion
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT00891475
Start Date
May 1 2008
End Date
January 1 2011
Last Update
February 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ilya Tsimafeyeu
Moscow, Russia, 109147